Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Friday's BioPlay: Xoma Ltd.
- Shares of Xoma Ltd. XOMA closed up 38% Thursday, a gain analysts pinned on anticipation that the drug company will release positive data on its Type II diabetes treatment during a presentation this weekend. In research notes Thursday, analysts said the new Phase I data on the drug, XOMA 052,...
- External links 2009-06-05
- Human Genome Sciences, GlaxoSmithKline: Diabetes Data Looks Good
- Here is a link to a press release issued yesterday by GlaxoSmithKline (NYSE:GSK), regarding new Phase 2 data for Syncria (R) albiglutide presented at the American Diabetes Association 69th Scientific Sessions in New Orleans. Late last week, we told our BioMedReports readers about Human Genome Sciences (NASDAQ:HGSI) who...
- External links 2009-06-09
- Medarex's "Holy Grail" Against Prostate Cancer Causes Surge in Share Price
- Prostate cancer is diagnosed in 192,000 U.S. men each year and 27,000 die. New screening tests have allowed more cases to be caught early, but the best treatment for large tumors that have spread to both lobes of the prostate has been the subject of debate. A new, effective treatment...
- External links 2009-06-23
- Positive News Ahead for Oculus Innovative Sciences
- I wanted to give our readers at BiomedReports and beyond a heads up about some news that may move Oculus' OCLS stock upward in the next day or so. This is a company that recently announced financial and operating results for the first quarter of fiscal year 2010, ended June...
- External links 2009-08-17
- Nephros Continues to Rise Ahead of FDA Decisions
- Nephros Inc. (NEPH.OB), the medical device company that engages in the development of hemodiafiltration (HDF) products and technologies for treating patients with end stage renal disease, has two more devices awaiting regulatory clearance from the FDA: The OLpur MD220 filter and OLpur H2H Hemodiafiltration module. The OLpur MD220...
- External links 2009-08-20
- Oculus's New Product Can Tap into Several Billion Dollar Markets
- This is not your typical biotech story. This is not a company waiting for a phase three study or an FDA decision in order to become profitable. This is now a commercial story with a company that is being very aggressive in their pursuit of additional revenues and a solid...
- External links 2009-08-21
- CEL-SCI CEO's Bullish Biotech Play
- CEL-SCI's CVM CEO is suddenly feeling more confident than ever. Who can blame him? There are verified reports that the company's biotechnology activates the immune system and targets the H1N1 flu's hemagglutinin molecule. The treatment apparently induces a defined immune response which could help infected swine...
- External links 2009-08-23
- Cel-Sci Thrives With New Manufacturing Facility
- New details have begun to emerge about Cel-Sci Corporation's CVM new, state-of-the-art "Cold-Fill" manufacturing facility which will not only be used to manufacture Multikine® the world's first immunotherapeutic agent (which is being developed as a first-line standard of care treatment for cancer) for both the Phase III trials and commercial...
- External links 2009-08-25
- Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume
- Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA,...
- External links 2009-09-01
- Allos Therapeutics: Prospects for FDA Approval of Folotyn Are Healthy
- After announcing that the U.S. Food and Drug Administration’s [FDA] Oncologic Drugs Advisory Committee [ODAC] voted 10-4 that the response rate and duration of response observed with FOLOTYNTM pralatrexate are reasonably likely to predict clinical benefit...
- External links 2009-09-04
- EpiCept Is on the Move
- Shares of EpiCept (NASDAQ: EPCT) are on the move as speculation about coming news had shares trading up more than 21% on Wednesday and even higher overnight in Europe where shares for the company are also traded on the NASDAQ OMX Nordic Exchange on Thursday morning. The Company possesses an...
- External links 2009-09-04
- Salix Pharma Continues to Rise in Anticipation of FDA Decision
- Shares of Salix Pharmaceuticals (NASDAQ:SLXP) have been rising in anticipation of their upcoming FDA decision, which is due this coming week. Shares for the company rose as much as 34% since July and on September 11, the FDA is scheduled to decide whether or not to approve the company's Metozolv...
- External links 2009-09-06
- Spectrum Pharma: Market Opportunities for Zevalin May Expand Significantly
- Following the presentation by Spectrum Pharmaceuticals SPPI, which was held in front of a standing room only crowd of institutional investors, hedge fund managers and Wall Street banker types at the Rodman & Renshaw Healthcare Conference in New York, Dr. Andrew Sandler was mobbed with questions from members of the...
- External links 2009-09-13
- Cel-Sci's Positive Momentum Keeps Building
- For years, it seems, CEL-SCI's CVM investors have been waiting for this perfect storm of positive developments. The company was so badly beaten and on the ropes recently, that most of the management team continued to work, for extended periods of time, without compensation. "When I came home...
- External links 2009-09-17
- Stage Set for Acorda Bounce?
- Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) have hit a five month low, after documents posted on the U.S. Food and Drug Administration's Website show that some agency investigators have questioned whether Acorda's proposed MS treatment Fampridine-SR should be approved. As subscribers to the BioMedReports FDA Calendar know, a special panel...
- External links 2009-10-11
- Epix Surrenders Battle to Keep Alzheimer's Program Afloat
- Even as they were announcing their FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patients, EPIX Pharmaceuticals, Inc. (OTC:EPIX) plans quietly to wind down operations after a hard fought battle to keep the company afloat. The Lexington, Mass.-based company’s officials said...
- External links 2009-10-19
- Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?
- Is the management at CEL-SCI Corporation CVM signaling that something big is coming? In mid September, on the same day that CEL-SCI Corporation announced that the U.S. Food and Drug Administration (FDA) had indicated that the company could proceed with its first clinical trial to evaluate the effect of its...
- External links 2009-11-12
- Law Firms Going After Hemispherx
- Accusations are heating up in the drama involving Hemispherx Biopharma, Inc (AMEX:HEB) and the law firms trying to go after the well capitalized biotech on behalf of investors. The latest of several law firms to jump on the company is led by Former Attorney General of Louisiana Charles C. Foti,...
- External links 2009-11-13
- CytRx Corporation: Key Developments Ahead
- The clouds of darkness that have been hanging over CytRx Corporation (NASDAQ:CYTR), may soon be cast aside. The stock, which has traded as low as $.24 earlier this year, appears to be on the rebound with at least two key developments on the horizon.On Friday morning, after seeing the stock...
- External links 2009-11-24
- SIGA Shares Could Double on Pending Government News
- BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.Our Subscribers were alerted Monday that a series of big government orders are...
- External links 2009-11-26
- << Previous
- page 1 of 2
- Next >>
Presented by American Express